July 10, 2025 03:00 AM EDT
Financing
Deals
Diagnostics

Aq­tu­al rais­es $31M to guide rheuma­toid arthri­tis treat­ments

Jared Whitlock

Features Editor

The di­ag­nos­tics com­pa­ny Aq­tu­al has raised $31 mil­lion to help de­vel­op its test that’s de­signed to pre­dict how pa­tients re­spond to rheuma­toid arthri­tis drugs. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Kid­ney health biotech emerges with $54M to fol­low in Ver­tex’s foot­steps

Ul­tragenyx, Mereo’s bone dis­ease drug fails sec­ond in­ter­im analy­sis, stocks plum­met

Swiss and Ger­man ra­dio­phar­ma biotech Nu­clid­i­um col­lects $99M Se­ries B

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times